Sagimet Biosciences Management
Management criteria checks 1/4
Sagimet Biosciences' CEO is Dave Happel, appointed in Oct 2022, has a tenure of 2.08 years. total yearly compensation is $2.69M, comprised of 18.7% salary and 81.3% bonuses, including company stock and options. directly owns 0.045% of the company’s shares, worth $64.60K. The average tenure of the management team and the board of directors is 1.7 years and 2.1 years respectively.
Key information
Dave Happel
Chief executive officer
US$2.7m
Total compensation
| CEO salary percentage | 18.7% |
| CEO tenure | 2.1yrs |
| CEO ownership | 0.04% |
| Management average tenure | 1.7yrs |
| Board average tenure | 2.1yrs |
Recent management updates
Recent updates
Sagimet: More Than Just A MASH Drug Development Biotech
Nov 14Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat
Oct 18Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide
Jul 31Companies Like Sagimet Biosciences (NASDAQ:SGMT) Are In A Position To Invest In Growth
May 31
Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity
Apr 26Sagimet: Additional Upside Possible After Latest NASH Data Release
Jan 24CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$38m |
| Jun 30 2024 | n/a | n/a | -US$29m |
| Mar 31 2024 | n/a | n/a | -US$28m |
| Dec 31 2023 | US$3m | US$503k | -US$28m |
| Sep 30 2023 | n/a | n/a | -US$27m |
| Jun 30 2023 | n/a | n/a | -US$28m |
| Mar 31 2023 | n/a | n/a | -US$28m |
| Dec 31 2022 | US$7m | US$98k | -US$30m |
Compensation vs Market: Dave's total compensation ($USD2.69M) is above average for companies of similar size in the US market ($USD653.78K).
Compensation vs Earnings: Dave's compensation has been consistent with company performance over the past year.
CEO
Dave Happel (62 yo)
2.1yrs
Tenure
US$2,685,917
Compensation
Mr. David A. Happel, also known as Dave, has been Chief Executive Officer and Director of Sagimet Biosciences Inc. since October 2022 and serves as its President since October 2022. From March 2020 through...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 9.1yrs | US$930.22k | 0.018% $ 25.4k | |
| CEO, President & Director | 2.1yrs | US$2.69m | 0.045% $ 64.6k | |
| Chief Medical Officer | 3.8yrs | US$1.51m | 0.044% $ 63.4k | |
| Co-Founder | no data | no data | no data | |
| Co-Founder | no data | no data | no data | |
| CFO & Principal Accounting Officer | less than a year | no data | no data | |
| General Counsel & Chief Compliance Officer | 1.6yrs | no data | 0.10% $ 144.4k | |
| Senior Vice President of Research & Development | 1.8yrs | no data | no data | |
| Senior Vice President of New Products | less than a year | no data | no data |
1.7yrs
Average Tenure
61yo
Average Age
Experienced Management: SGMT's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 9.1yrs | US$930.22k | 0.018% $ 25.4k | |
| CEO, President & Director | 2.1yrs | US$2.69m | 0.045% $ 64.6k | |
| Independent Director | 17.6yrs | US$14.38k | 0.41% $ 595.0k | |
| Independent Director | 3.6yrs | US$43.00k | 0% $ 0 | |
| Independent Director | less than a year | no data | 0.0069% $ 9.9k | |
| Independent Director | 14.2yrs | US$41.50k | 0.040% $ 57.8k | |
| Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Director | less than a year | no data | no data |
2.1yrs
Average Tenure
61yo
Average Age
Experienced Board: SGMT's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.